UltraThera Technologies, Inc.

UltraThera Technologies, Inc. manufactures GyroStim, an FDA-cleared Breakthrough Device for multimodal neurorehabilitation. GyroStim is a precision neurotechnology platform engineered to accelerate recovery from concussion, mild traumatic brain injury (mTBI), and vestibular dysfunction. The device combines rotational motion with precisely dosed therapeutic protocols to address balance disorders and neurological impairments. Clinical evidence demonstrates up to 8× faster rehabilitation rates compared to conventional therapy alone. FDA-cleared under K220231 for treatment of balance disorders and vestibular dysfunction, GyroStim holds the rare FDA Breakthrough Device designation, recognizing its capability to significantly advance standard-of-care outcomes. The system has been in continuous clinical use since 2010 with zero reported injuries. GyroStim is accessible to patients across a broad severity spectrum, including those with severe physical or cognitive disabilities who may not tolerate traditional therapies. The platform is used by elite athletes, military personnel, civilians, and patients in specialized neurorehabilitation centers worldwide. Applications include sports-related concussion recovery, traumatic brain injury rehabilitation, vestibular rehabilitation, and performance optimization. The company provides clinical outcome data, physician training, and patient support services. Manufacturing and regulatory compliance align with medical device standards for rehabilitation and neurological therapeutic equipment.